Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Mark Ragosa Sells 17,845 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 17,845 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. The trade was a 59.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Thursday, January 8th, Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.89, for a total value of $502,680.00.
• On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.49, for a total value of $1,777,473.09.

Kiniksa Pharmaceuticals International Trading Up 0.6%

NASDAQ:KNSA opened at $44.98 on Thursday. The stock has a 50-day moving average price of $42.06 and a 200 day moving average price of $38.68. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.25 and a 12-month high of $45.50. The stock has a market capitalization of $3.41 billion, a P/E ratio of 99.96 and a beta of 0.06.

Analysts Set New Price Targets

A number of analysts have issued reports on KNSA shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Zacks Research cut Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $52.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the period. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. USA Financial Formulas bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter worth $41,000. Finally, Quantbot Technologies LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.